IL162929A0 - Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization - Google Patents
Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallizationInfo
- Publication number
- IL162929A0 IL162929A0 IL16292903A IL16292903A IL162929A0 IL 162929 A0 IL162929 A0 IL 162929A0 IL 16292903 A IL16292903 A IL 16292903A IL 16292903 A IL16292903 A IL 16292903A IL 162929 A0 IL162929 A0 IL 162929A0
- Authority
- IL
- Israel
- Prior art keywords
- lasofoxifene
- recrystallization
- purification
- purified
- racemic
- Prior art date
Links
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title 2
- 229960002367 lasofoxifene Drugs 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
- 238000001953 recrystallisation Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36887202P | 2002-03-28 | 2002-03-28 | |
| PCT/IB2003/001033 WO2003082814A1 (fr) | 2002-03-28 | 2003-03-17 | Lasofoxifene purifie et procede de purification du lasofoxifene racemique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162929A0 true IL162929A0 (en) | 2005-11-20 |
Family
ID=28675551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16292903A IL162929A0 (en) | 2002-03-28 | 2003-03-17 | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
| IL162929A IL162929A (en) | 2002-03-28 | 2004-07-08 | Methods of purifying sophisticated sufoxifen by reconstitution |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162929A IL162929A (en) | 2002-03-28 | 2004-07-08 | Methods of purifying sophisticated sufoxifen by reconstitution |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6906202B2 (fr) |
| EP (1) | EP1487790B1 (fr) |
| JP (1) | JP4268055B2 (fr) |
| KR (1) | KR100636953B1 (fr) |
| CN (1) | CN1283625C (fr) |
| AR (1) | AR039152A1 (fr) |
| AT (1) | ATE459599T1 (fr) |
| AU (1) | AU2003209603B2 (fr) |
| BR (1) | BR0308758A (fr) |
| CA (1) | CA2479924C (fr) |
| DE (1) | DE60331527D1 (fr) |
| DK (1) | DK1487790T3 (fr) |
| ES (1) | ES2339936T3 (fr) |
| HU (1) | HUP0500025A3 (fr) |
| IL (2) | IL162929A0 (fr) |
| MX (1) | MXPA04009259A (fr) |
| PL (1) | PL372727A1 (fr) |
| RS (1) | RS80604A (fr) |
| RU (1) | RU2278861C2 (fr) |
| TW (1) | TW200306974A (fr) |
| WO (1) | WO2003082814A1 (fr) |
| ZA (1) | ZA200405209B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1487790T3 (da) * | 2002-03-28 | 2010-05-10 | Pfizer Prod Inc | Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering |
| WO2007095161A2 (fr) * | 2006-02-14 | 2007-08-23 | New York University | Méthodes et compositions pour traiter des troubles associés à une augmentation du renouvellement osseux et une ostéopénie |
| CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| KR102412089B1 (ko) | 2021-09-13 | 2022-06-22 | 주식회사 세라수 | Dmts의 정제방법 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| AU2024328571A1 (en) | 2023-08-21 | 2026-03-12 | Duke University | Treatment of solid cancer with lasofoxifene |
| KR102663941B1 (ko) | 2024-03-04 | 2024-05-08 | 주식회사 세라수 | Drometrizole trisiloxane(DMTS)의 제조방법 |
| WO2026095931A1 (fr) | 2024-10-30 | 2026-05-07 | Sermonix Pharmaceuticals, Inc. | Traitement néoadjuvant du cancer du sein er+ avec du lasofoxifène |
| WO2026096820A1 (fr) | 2024-10-30 | 2026-05-07 | Sermonix Pharmaceuticals, Inc. | Traitement néoadjuvant du cancer du sein er+ avec du lasofoxifène |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903111A (en) * | 1972-09-11 | 1975-09-02 | Sandoz Ltd | 4-{8 3-Phenyl-pyrrolidin-1-yl{9 -butyrophenone derivatives |
| US5326865A (en) * | 1990-06-08 | 1994-07-05 | Hercules Incorporated | Arylazo and poly(arylazo) dyes having at least one core radical selected from naphthyl or anthracyl and having at least one 2,3-dihydro-1,3-dialkyl perimidine substituent |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| EP0756205A3 (fr) * | 1995-07-26 | 1998-10-14 | Eastman Kodak Company | Techniques pour transférer des motifs dans la fabrication de réseaux de lentilles en utilisant des polyesters spéciaux |
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| EP1086692A3 (fr) * | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Agonistes et antagonistes de l'estrogène pour des indications multiples |
| US6180375B1 (en) * | 1999-08-27 | 2001-01-30 | Pfizer Inc. | Microbial biotransformation |
| IL158390A0 (en) | 2001-05-01 | 2004-05-12 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
| DK1487790T3 (da) * | 2002-03-28 | 2010-05-10 | Pfizer Prod Inc | Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering |
-
2003
- 2003-03-17 DK DK03745203.4T patent/DK1487790T3/da active
- 2003-03-17 HU HU0500025A patent/HUP0500025A3/hu unknown
- 2003-03-17 ES ES03745203T patent/ES2339936T3/es not_active Expired - Lifetime
- 2003-03-17 PL PL03372727A patent/PL372727A1/xx not_active Application Discontinuation
- 2003-03-17 WO PCT/IB2003/001033 patent/WO2003082814A1/fr not_active Ceased
- 2003-03-17 CA CA002479924A patent/CA2479924C/fr not_active Expired - Fee Related
- 2003-03-17 BR BR0308758-1A patent/BR0308758A/pt not_active IP Right Cessation
- 2003-03-17 RU RU2004128931/04A patent/RU2278861C2/ru not_active IP Right Cessation
- 2003-03-17 KR KR1020047015249A patent/KR100636953B1/ko not_active Expired - Fee Related
- 2003-03-17 DE DE60331527T patent/DE60331527D1/de not_active Expired - Lifetime
- 2003-03-17 CN CNB038031175A patent/CN1283625C/zh not_active Expired - Lifetime
- 2003-03-17 RS YUP-806/04A patent/RS80604A/sr unknown
- 2003-03-17 EP EP03745203A patent/EP1487790B1/fr not_active Expired - Lifetime
- 2003-03-17 MX MXPA04009259A patent/MXPA04009259A/es active IP Right Grant
- 2003-03-17 AT AT03745203T patent/ATE459599T1/de not_active IP Right Cessation
- 2003-03-17 AU AU2003209603A patent/AU2003209603B2/en not_active Ceased
- 2003-03-17 IL IL16292903A patent/IL162929A0/xx unknown
- 2003-03-17 JP JP2003580282A patent/JP4268055B2/ja not_active Expired - Fee Related
- 2003-03-26 US US10/397,654 patent/US6906202B2/en not_active Expired - Lifetime
- 2003-03-26 AR ARP030101058A patent/AR039152A1/es unknown
- 2003-03-27 TW TW092106928A patent/TW200306974A/zh unknown
-
2004
- 2004-06-30 ZA ZA2004/05209A patent/ZA200405209B/en unknown
- 2004-07-08 IL IL162929A patent/IL162929A/en active IP Right Grant
-
2005
- 2005-03-28 US US11/092,240 patent/US7358374B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003297844A1 (en) | Methods for reducing latency of a call set up | |
| IL166523A0 (en) | Generalized metronome for modification of biorhythmic activity | |
| SI1590061T1 (sl) | Metoda za äśiĺ äśenje alfa-1-antitripsina | |
| HUP0500025A3 (en) | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization | |
| SI1578695T1 (sl) | Postopek za odstranitev biofilma | |
| GB2389179B (en) | A method of electrophoresis | |
| IL195370A0 (en) | A crystallization method for purification of calcipotriene | |
| AU2003215781A8 (en) | Method for production of phytoalexins | |
| EP1562900A4 (fr) | Polymorphes du chlorhydrate de bicifadine | |
| IL163429A (en) | Process for preparing a phenylalanine derivative and intermediates thereof | |
| IL165115A0 (en) | Novel crystalline forms of gatifloxacin | |
| TWI347932B (en) | Producing method of purified 2-cyanoacrylates | |
| EP1512783A4 (fr) | Procede de tricotage de bonneterie | |
| IL166592A0 (en) | Novel crystalline forms of gatifloxacin | |
| AUPS334902A0 (en) | Purification method | |
| GB0224049D0 (en) | Removal of nitrogen compounds | |
| PL353509A1 (en) | Method of purification of 5-aminolevulline acid hydrochloride | |
| EP1486485A4 (fr) | Nouveaux cristaux de derive de 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide | |
| AU2003243153A8 (en) | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof | |
| AU2003258982A8 (en) | Methods of inhibiting pin1-associated states using a fredericamycin a compound | |
| AU2003296180A1 (en) | Method for purification of milbemycins | |
| AU2003270107A1 (en) | Purification method for fredericamycin a | |
| GB0228795D0 (en) | Improvement to a device for correction of distortion | |
| TWI366564B (en) | Novel crude and crystalline forms of lercanidipine hydrochloride | |
| TWI346106B (en) | Novel crude and crystalline forms of lercanidipine hydrochloride |